Baseline characteristics

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · Source last updated 2018-06-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      1

   2. group Id

      BG001

      value

      13

   3. group Id

      BG002

      value

      14

   units

   Participants

groups

1. description

   Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. alisertib: Given PO rituximab: Given IV laboratory biomarker analysis: Laboratory correlative studies will be performed

   id

   BG000

   title

   Cohort A (Alisertib, Rituximab)

2. description

   Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. alisertib: Given PO rituximab: Given IV laboratory biomarker analysis: Laboratory correlative studies will be performed

   id

   BG001

   title

   Cohort B (Alisertib, Rituximab)

3. description

   Total of all reporting groups

   id

   BG002

   title

   Total

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            77

            upper Limit

            77

            value

            77

         2. group Id

            BG001

            lower Limit

            35

            upper Limit

            73

            value

            58

         3. group Id

            BG002

            lower Limit

            35

            upper Limit

            77

            value

            67.5

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            0

         2. group Id

            BG001

            value

            3

         3. group Id

            BG002

            value

            3

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            1

         2. group Id

            BG001

            value

            10

         3. group Id

            BG002

            value

            11

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            1

         2. group Id

            BG001

            value

            13

         3. group Id

            BG002

            value

            14

      title

      United States

   param Type

   NUMBER

   title

   Region of Enrollment

   unit Of Measure

   patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice